Search by keyword.
Radiopharmaceuticals are opening new opportunities for targeted diagnosis and therapy, but their development requires a careful balance of targeting, linker design, stability, and drug-like properties. At SpiroChem, we combine deep expertise in medicinal and synthetic chemistry with our capabilities in linker and conjugate design to support the discovery of innovative radiopharmaceuticals.
From early design and hit identification to the synthesis and optimization of complex radiopharmaceutical building blocks and conjugates, we help our partners overcome challenging chemistry and accelerate the journey toward selective, potent, and developable candidates.
Our collaboration with ITM Isotope Technologies Munich (ITM) is a strong example of how our drug discovery capabilities can support the identification and optimization of novel radiopharmaceutical targeting agents. By combining SpiroChem’s macrocycle libraries, screening engine, and medicinal chemistry expertise with ITM’s radiopharmaceutical development capabilities, the collaboration aims to identify high-affinity binders and advance novel chemical matter toward potential radiopharmaceutical candidates.
